PropertyValue
?:abstract
  • Eli Lilly and Company and Regeneron have applied to the US Food and Drug Administration for emergency use authorizations (EUAs) for their COVID-19 monoclonal antibodies, which block the entry of SARS-CoV-2 into human cells Both firms have released early data from clinical trials showing that their antibodies reduce viral load and have some effect on symptoms Regeneron, which provided its treatment to President Donald J Trump, has said it will initially make the drug available for free;Lilly has said it would like to do the same [ ]
is ?:annotates of
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Lilly, Regeneron seek EUAs for COVID drugs
?:type
?:who_covidence_id
  • #851234
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/k0rthcds>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/k0rthcds>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all